Eton Pharmaceuticals (ETON) Other Non-Current Liabilities (2017 - 2026)
Eton Pharmaceuticals (ETON) posted Other Non-Current Liabilities of $5.2 million for Q4 2025, up 32.95% sequentially from $3.9 million in Q3 2025, and up 186.39% YoY from $1.8 million in Q4 2024.
Eton Pharmaceuticals (ETON) Other Non-Current Liabilities (2017 - 2026) Analysis & Trends
Eton Pharmaceuticals has reported Other Non-Current Liabilities for 4 years, with the latest figure at $5.2 million in Q4 2025.
- Quarterly Other Non-Current Liabilities rose 186.39% year-over-year to $5.2 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $5.2 million (up 186.39% YoY) and the FY2025 annual result came in at $5.2 million, up 186.39% from the prior year.
- Other Non-Current Liabilities rose to $5.2 million in Q4 2025 per ETON's latest filing, from $3.9 million in the prior quarter.
- Over five years, Other Non-Current Liabilities peaked at $5.2 million in Q4 2025 and troughed at $1.8 million in Q4 2024.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Haleon | 43.94 Bn | 42.97 Bn | - |
| 2 | Teva Pharmaceutical Industries | 43.08 Bn | 39.43 Bn | 2.15 Bn |
| 3 | Zoetis | 31.54 Bn | 29.87 Bn | 1.05 Bn |
| 4 | Takeda Pharmaceutical | 28.60 Bn | 22.80 Bn | 5.10 Bn |
| 5 | United Therapeutics | 22.12 Bn | 19.46 Bn | 683.80 Mn |
| 6 | Viatris | 18.75 Bn | 17.86 Bn | 1.46 Bn |
| 7 | Neurocrine Biosciences | 15.50 Bn | 15.11 Bn | 935.80 Mn |
| 8 | Elanco Animal Health | 11.69 Bn | 11.16 Bn | 798.00 Mn |
| 9 | Dr Reddys Laboratories | 10.13 Bn | 9.96 Bn | - |
| 10 | Eton Pharmaceuticals | 1.67 Bn | 1.64 Bn | 25.41 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 3.94 Mn |
| Dec 31, 2025 | 5.24 Mn |
| Sep 30, 2025 | 3.94 Mn |
| Jun 30, 2025 | 4.27 Mn |
| Mar 31, 2025 | 4.15 Mn |
| Dec 31, 2024 | 1.83 Mn |
| Sep 30, 2018 | 1.58 Mn |
| Dec 31, 2017 | 520,000.00 |